Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nellcor gets US nod for adhesive-free sensors:

This article was originally published in Clinica

Executive Summary

Nellcor has gained US FDA 510(k) clearance to sell its SoftCare family of adhesive-free pulse oximetry sensors, which are designed to protect the delicate skin of neonates, geriatrics and other patients with compromised skin integrity. Designed for use with the firm's OxiMax pulse oximeters and other manufacturers' multi-parameter monitoring systems equipped with the OxiMax technology, the sensors fastens around the sensor site with Velcro instead of adhesive tape to eliminate adhesive-related skin trauma. Research has shown that adhesives are the primary cause of skin breakdown among neonatal intensive care unit patients, says the Pleasanton, California firm. Pulse oximetry sensors were cited as one of the therapeutic interventions that can potentially cause skin injury.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT062750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel